Literature DB >> 194247

Immune surveillance against virus-induced tumors and nonrejectability of spontaneous tumors: contrasting consequences of host versus tumor evolution.

G Klein, E Klein.   

Abstract

Spontaneous tumours are defined as tumors that develop in the absence of all experimental interference. In contrast to the widely documented, strong rejection reactions against most virus-induced tumors, spontaneous tumors evoke little or no detectable rejection reaction in intact or preimmunized syngeneic hosts. The difference can be viewed in relation to the contrasting natural history of the two conditions. Spontaneous tumors evolve in several steps, as a fule. "Tumor progression" is a microevolutionary process at the level of the somatic tissue where successive clonal variants replace each other. Each new variant gains the upper hand due to its greater independence of some restricting host mechanism. Independence of immune restrictions must be part of this process. Host selection for immune resistance apparently plays no major role here, presumably because most of the naturally occurring tumors arise after the host has passed the peak of its reproductive period. Protection against the oncogenic effects of ubiquitous tumor viruses is, on the other hand, the result of host selection for immune mechanisms favoring prompt rejection of virus-transformed cells. This is neither synonymous with nor related to protection against the viral infection per se, which is frequently successful and usually quite harmless. A certain relationship can be perceived between the degree of viral ubiquity and the strength of immune protection against the corresponding tumor cells. Natural selection for host recognition of commonly occurring, virally induced changes in neoplastic cell membranes can be surmised to occur, at least in part, by the fixation of appropriate immune responsiveness (Ir) genes. The role of Ir genes for tumor recognition can be approached by the genetic analysis of the F1 hybrid resistance effect. Unresponsiveness to spontaneous tumors may be overcome by target-cell modification, e.g., by chemical coupling, somatic cell hybridization, or viral "xenogenization".

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 194247      PMCID: PMC431087          DOI: 10.1073/pnas.74.5.2121

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

1.  Present status of nonviral factors in the etiology of reticular neoplasms of the mouse.

Authors:  L W LAW
Journal:  Ann N Y Acad Sci       Date:  1957-10-21       Impact factor: 5.691

2.  The natural history of cancer.

Authors:  L FOULDS
Journal:  J Chronic Dis       Date:  1958-07

3.  Killer T cells in a Burkitt's lymphoma biopsy.

Authors:  M Jondal; E Svedmyr; E Klein; S Singh
Journal:  Nature       Date:  1975-05-29       Impact factor: 49.962

4.  From the molecular biology of oncogenic DNA viruses to cancer.

Authors:  R Dulbecco
Journal:  Science       Date:  1976-04-30       Impact factor: 47.728

5.  "Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype.

Authors:  R Kiessling; E Klein; H Wigzell
Journal:  Eur J Immunol       Date:  1975-02       Impact factor: 5.532

6.  Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells.

Authors:  R B Herberman; M E Nunn; H T Holden; D H Lavrin
Journal:  Int J Cancer       Date:  1975-08-15       Impact factor: 7.396

7.  "Natural" killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell.

Authors:  R Kiessling; E Klein; H Pross; H Wigzell
Journal:  Eur J Immunol       Date:  1975-02       Impact factor: 5.532

8.  Genetic variation of in vitro cytolytic activity and in vivo rejection potential of non-immunized semi-syngeneic mice against a mouse lymphoma line.

Authors:  R Kiessling; G Petranyi; G Klein; H Wigzel
Journal:  Int J Cancer       Date:  1975-06-15       Impact factor: 7.396

9.  Trisomy of chromosome 15 in spontaneous leukemia of AKR mice.

Authors:  R Dofuku; J L Biedler; B A Spengler; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1975-04       Impact factor: 11.205

10.  Killer cells: a functional comparison between natural, immune T-cell and antibody-dependent in vitro systems.

Authors:  R Kiessling; G Petranyi; K Kärre; M Jondal; D Tracey; H Wigzell
Journal:  J Exp Med       Date:  1976-04-01       Impact factor: 14.307

View more
  45 in total

Review 1.  Targeting stroma to treat cancers.

Authors:  Boris Engels; Donald A Rowley; Hans Schreiber
Journal:  Semin Cancer Biol       Date:  2011-12-24       Impact factor: 15.707

Review 2.  In situ vaccination with nanoparticles for cancer immunotherapy: understanding the immunology.

Authors:  Chenkai Mao; Michael-Joseph Gorbet; Akansha Singh; Ashish Ranjan; Steven Fiering
Journal:  Int J Hyperthermia       Date:  2020-12       Impact factor: 3.914

3.  T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF-β1 cytokine.

Authors:  Moses K Donkor; Abira Sarkar; Peter A Savage; Ruth A Franklin; Linda K Johnson; Achim A Jungbluth; James P Allison; Ming O Li
Journal:  Immunity       Date:  2011-07-14       Impact factor: 31.745

4.  Early manifestations of NNK-induced lung cancer: role of lung immunity in tumor susceptibility.

Authors:  Seddigheh Razani-Boroujerdi; Mohan L Sopori
Journal:  Am J Respir Cell Mol Biol       Date:  2006-07-27       Impact factor: 6.914

Review 5.  Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy.

Authors:  Pierre G Coulie; Benoît J Van den Eynde; Pierre van der Bruggen; Thierry Boon
Journal:  Nat Rev Cancer       Date:  2014-02       Impact factor: 60.716

Review 6.  The role of immunosuppression in lymphoma formation.

Authors:  I Penn
Journal:  Springer Semin Immunopathol       Date:  1998

Review 7.  The determinants of tumour immunogenicity.

Authors:  Thomas Blankenstein; Pierre G Coulie; Eli Gilboa; Elizabeth M Jaffee
Journal:  Nat Rev Cancer       Date:  2012-03-01       Impact factor: 60.716

8.  Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance.

Authors:  Gerald Willimsky; Karin Schmidt; Christoph Loddenkemper; Johanna Gellermann; Thomas Blankenstein
Journal:  J Clin Invest       Date:  2013-02-01       Impact factor: 14.808

9.  Immune complexes and circulating antibodies against autologous leukaemic cells in patients with acute leukaemias.

Authors:  M Bertini; G Galetto; P M Comoglio
Journal:  Immunology       Date:  1982-03       Impact factor: 7.397

Review 10.  Natural and induced immunity to mouse mammary tumors and the mammary tumor virus (MuMTV).

Authors:  O Stutman
Journal:  Springer Semin Immunopathol       Date:  1982
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.